Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- SQZ Biotechnologies
- Target Recruit Count
- 30
- Registration Number
- NCT04084951
- Locations
- 🇺🇸
University of Colorado Anschutz Cancer Pavillion, Aurora, Colorado, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸University of Kansas Cancer Center, Kansas City, Kansas, United States
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Dan Zandberg
- Target Recruit Count
- 80
- Registration Number
- NCT04080804
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT04079712
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)
- Conditions
- Interventions
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Hatim Husain
- Target Recruit Count
- 30
- Registration Number
- NCT04043195
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT04042753
- Locations
- 🇺🇸
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 732
- Registration Number
- NCT04039607
- Locations
- 🇺🇸
Local Institution - 0295, Newark, New Jersey, United States
🇧🇷Local Institution - 0061, Salvador, Bahia, Brazil
🇦🇺Local Institution - 0038, Liverpool, New South Wales, Australia
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 925
- Registration Number
- NCT04026412
- Locations
- 🇺🇸
Local Institution - 0071, Burlington, Vermont, United States
🇺🇸Local Institution - 0124, Cleveland, Ohio, United States
🇺🇸Local Institution - 0053, Cincinnati, Ohio, United States
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
- Conditions
- Interventions
- First Posted Date
- 2019-07-16
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 68
- Registration Number
- NCT04021043
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
- Conditions
- Interventions
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 67
- Registration Number
- NCT04013854
- Locations
- 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States
🇺🇸Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Lancaster General Hospital, Lancaster, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.